MDLN
SHORTINSIDER SELLMEDLINE INC
Research: Finviz ↗·Perplexity ↗
🗄 Viewing archived Q2 2026 data — frozen, no longer refreshed.
News Summary
NeutralMedline delivered strong Q3 earnings with 10% revenue growth and 12% EBITDA growth, beating expectations and raising full-year organic sales guidance for the third consecutive quarter, supported by analyst upgrades and a $1B share repurchase. However, significant headwinds persist: an FDA warning letter for manufacturing violations in June 2026, resulting remediation costs that reduced Q2 earnings, a major product line exit (Front Line Care) in October, and ongoing securities fraud investigations by multiple law firms.
Red flags
- •FDA warning letter (June 2026) for significant Current Good Manufacturing Practice violations in finished pharmaceuticals
- •Q2 net income down 58.3% year-over-year; remediation of FDA issues acknowledged as causing 'earnings loss'
- •Exited Front Line Care product category (October 2026) with inventory impairment and disposal costs
- •Multiple securities fraud investigations underway by Bleichmar Fonti & Auld, Pomerantz, and others regarding manufacturing and product quality disclosures
- •Board director resignation and transition disclosed in late October 2026
Funds Reducing / Exiting (4)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Viking Global | Andreas Halvorsen | 4.8M | -6,592,741 | $191M | 1.4% | -58% | Existing |
| Durable Capital Partners | Henry Ellenbogen | 2.6M | -4,638,500 | $104M | 3.3% | -64% | Existing |
| Maverick Capital | Lee Ainslie | 0 | −796K | — | 0.4% | -100% | EXITED |
| Point72 | Steve Cohen | 0 | −3.3M | — | 0.3% | -100% | EXITED |
Shares Held reflects quarter-end positions for partial reductions. Funds that fully exited show 0 shares held. ∆ Shares is the change from the prior quarter. % of Fund is the prior-quarter position size — how much of the book was sold down.
Signal History
Same issuer appearing in consecutive quarters — persistent institutional conviction. Returns are frozen at each archived quarter's last refresh.
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed | Src |
|---|---|---|---|---|---|---|---|
| GIC Private Ltd | — | SELL | 7.8M | $35.15 | $274.77M | 2026-10-08 | ↗ |
| GIC Private Ltd | — | SELL | 2.1M | $35.05 | $73.22M | 2026-10-06 | ↗ |
| GIC Private Ltd | — | SELL | 7.2M | $35.05 | $251.76M | 2026-10-06 | ↗ |
| GIC Private Ltd | — | SELL | 1.7M | $35.78 | $60.42M | 2026-10-05 | ↗ |
| GIC Private Ltd | — | SELL | 7.1M | $34.33 | $245.35M | 2026-10-02 | ↗ |
| GIC Private Ltd | — | SELL | 2.6M | $35.35 | $90.88M | 2026-10-02 | ↗ |
| GIC Private Ltd | — | SELL | 100K | $35.80 | $3.58M | 2026-08-14 | ↗ |
| GIC Private Ltd | — | SELL | 1.5M | $35.80 | $53.70M | 2026-08-13 | ↗ |
| GIC Private Ltd | — | SELL | 590K | $35.58 | $21.00M | 2026-08-07 | ↗ |
| GIC Private Ltd | — | SELL | 272K | $35.33 | $9.61M | 2026-08-06 | ↗ |
| GIC Private Ltd | — | SELL | 1.7M | $35.46 | $60.67M | 2026-08-05 | ↗ |
| GIC Private Ltd | — | SELL | 266K | $36.48 | $9.69M | 2026-08-05 | ↗ |
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| Capital Research Global Investors | SC 13G | 47.8M | 5.4% | 2026-11-13 | ↗ |
| GIC Private Limited | SC 13G/A | 74.6M | 8.5% | 2026-11-06 | ↗ |
| GIC Private Limited | SC 13G/A | 114.4M | 13.0% | 2026-10-30 | ↗ |
| Hellman & Friedman Capital Partners X (Parallel), L.P. | SC 13G/A | 61.1M | 6.4% | 2026-08-11 | ↗ |
| BX Mozart ML-2 Holdco L.P. | SC 13G/A | 89.5M | 10.2% | 2026-08-07 | ↗ |
| FMR LLC | SC 13G | 46.9M | 5.5% | 2026-08-06 | ↗ |
| Carlyle Group Inc. | SC 13G/A | 187.1M | 20.6% | 2026-05-15 | ↗ |
| Abu Dhabi Investment Authority | SC 13G/A | 41.4M | 4.9% | 2026-05-07 | ↗ |
| Hellman & Friedman Capital Partners X (Parallel), L.P. | SC 13G/A | 74.5M | 7.9% | 2026-05-06 | ↗ |
| BX Mozart ML-2 Holdco L.P. | SC 13G/A | 109.3M | 12.9% | 2026-05-01 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.